Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus - ScienceDirect
Development of Anti-CD20 Antigen-Targeting Therapies for B-cell Lymphoproliferative Malignancies - The State of the Art | Bentham Science
Frontiers | Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better? | SpringerLink
CD-20 | ドライブレコーダー | セルスター工業株式会社
CD20 CD3 Cancer Immunity Targets | Genentech Oncology
Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab | Nature Communications
CD20 positive CD8 T cells are a unique and transcriptionally-distinct subset of T cells with distinct transmigration properties | Scientific Reports
Anti-CD20–mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives - Kidney International
Frontiers | Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Cells | Free Full-Text | Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients | HTML
CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies | Bentham Science
B cell depletion therapies in autoimmune disease: advances and mechanistic insights | Nature Reviews Drug Discovery
CD antigens expression in B cells
Potential anti-CD20 mAb effector mechanisms. (A) Fc-Fc ␥ R–dependent... | Download Scientific Diagram
CD20 as a gatekeeper of the resting state of human B cells | PNAS
The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis | BMC Cancer | Full Text
Anti-CD20 Antibody Therapy for B-Cell Lymphomas | NEJM
CD20 - Wikipedia
